Earnings ·
Ionis Pharmaceuticals reported second quarter 2026 financial results, posting total revenue of $268 million compared…
IONSIonis Pharmaceuticals Inc
Ionis Pharmaceuticals reported second quarter 2026 financial results, posting total revenue of $268 million compared to $452 million in the prior year period. The decline was primarily driven by a significant drop in research and development revenue from collaborative agreements, which fell to $133 million from $337 million, excluding a one-time $280 million upfront payment received in Q2 2025 for sapablursen. Commercial revenue increased to $119 million from $103 million, supported by TRYNGOLZA net sales of $5 million and DAWNZERA net sales of $26 million. The company reported a net loss of $115 million, or $0.69 per diluted share, compared to net income of $124 million in the prior year. Operating expenses rose to $370 million due to commercialization investments for TRYNGOLZA and DAWNZERA. Ionis maintains a cash position of $2.1 billion and remains on track to achieve its 2026 financial guidance and cash flow breakeven by 2028. The company operates in the biotechnology industry, specializing in RNA-targeted medicines for neurology and cardiometabolic diseases.